Posted by Michael Wonder on 25 Aug 2021
NICE publishes appraisal guidance on new medicine for patients with biliary tract cancer
25 August 2021 - Pemigatinib (Pemaryze, Incyte) has a conditional marketing authorisation for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Pemigatinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that has progressed after systemic therapy in adults.
It is recommended only if Incyte provides pemigatinib according to the commercial arrangement.
